Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R. Westin, Anna Sureda, Michael Dickinson et al.|Clinical Cancer Research|2023Cited by 51
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Blood Cancer Discovery|2023Cited by 49
Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients with Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)Jason R. Westin, Frederick L. Locke, Marie José Kersten et al.|Transplantation and Cellular Therapy|2025Cited by 1
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0